BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19257794)

  • 1. Analysis of correlations between energy and residue fluctuations in native proteins and determination of specific sites for binding.
    Haliloglu T; Erman B
    Phys Rev Lett; 2009 Feb; 102(8):088103. PubMed ID: 19257794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease.
    Piana S; Carloni P; Parrinello M
    J Mol Biol; 2002 May; 319(2):567-83. PubMed ID: 12051929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical thermodynamics of residue fluctuations in native proteins.
    Yogurtcu ON; Gur M; Erman B
    J Chem Phys; 2009 Mar; 130(9):095103. PubMed ID: 19275429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations.
    Kurt N; Scott WR; Schiffer CA; Haliloglu T
    Proteins; 2003 May; 51(3):409-22. PubMed ID: 12696052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A semiempirical free energy force field with charge-based desolvation.
    Huey R; Morris GM; Olson AJ; Goodsell DS
    J Comput Chem; 2007 Apr; 28(6):1145-52. PubMed ID: 17274016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gaussian network model: precise prediction of residue fluctuations and application to binding problems.
    Erman B
    Biophys J; 2006 Nov; 91(10):3589-99. PubMed ID: 16935951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of human immunodeficiency virus protease cleavage sites in proteins.
    Chou KC
    Anal Biochem; 1996 Jan; 233(1):1-14. PubMed ID: 8789141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrete breathers in nonlinear network models of proteins.
    Juanico B; Sanejouand YH; Piazza F; De Los Rios P
    Phys Rev Lett; 2007 Dec; 99(23):238104. PubMed ID: 18233417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
    Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
    Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
    Lu Y; Yang CY; Wang S
    J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model.
    Wang W; Kollman PA
    J Mol Biol; 2000 Nov; 303(4):567-82. PubMed ID: 11054292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An estimation method of binding free energy in terms of ABEEMσπ/MM and continuum electrostatics fused into LIE method.
    Chen SL; Zhao DX; Yang ZZ
    J Comput Chem; 2011 Jan; 32(2):338-48. PubMed ID: 20662079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the binding energy for small molecules, peptides and proteins.
    Schapira M; Totrov M; Abagyan R
    J Mol Recognit; 1999; 12(3):177-90. PubMed ID: 10398408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
    Yan GW; Chen Y; Li Y; Chen HF
    Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations.
    Verkhivker GM
    Pac Symp Biocomput; 1996; ():638-52. PubMed ID: 9390264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic flaps in HIV-1 protease adopt unique ordering at different stages in the catalytic cycle.
    Karthik S; Senapati S
    Proteins; 2011 Jun; 79(6):1830-40. PubMed ID: 21465560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between ligand binding sites, protein architecture and correlated paths of energy and conformational fluctuations.
    Erman B
    Phys Biol; 2011 Oct; 8(5):056003. PubMed ID: 21832802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.